Full Press Release Details
Orgenesis Inc. Appoints Ex FDA Officer and Diabetes
Authority to Scientific Advisory Board
WHITE PLAINS, NY (MARKETWIRE April 23, 2012) Orgenesis
Inc. (OTCBB: ORGS) ( Orgenesis or the Company ), a development
stage company with a novel therapeutic technology dedicated to convert a
patient s own liver cells into functional insulin-producing cells as a treatment
for diabetes, is very pleased to announce the appointment of Dr. G. Alexander
Fleming, M.D. to the Company s Scientific Advisory Board.
Dr. Fleming is a board certified endocrinologist with medical
and research training at Emory, Vanderbilt, and National Institutes of Health.
He served as reviewer and supervisory medical officer for 12 years at the FDA
and brings extensive clinical experience and regulatory responsibility in the
therapeutic area of diabetes and other general metabolic, bone, and endocrine
disorders, growth and development, nutrition, lipid-lowering compounds, and
reproductive indications. He led reviews of landmark approvals including those
of the first statin, insulin analog, metformin, PPAR-agonist, and growth hormone
for non-GH deficiency indications. He was responsible for the regulation of the
earliest biotech products including human insulin and growth hormone. Dr.
Fleming helped to shape a number of FDA policies and practices related to
therapeutic review and regulatory communication and represented FDA at the
International Conference on Harmonisation (ICH) and the World Health
Organization, where he was stationed in 1992-93.
He serves on numerous scientific advisory boards, expert
committees, and corporate boards. He has continued to promote dialogue and
creativity within the community of therapeutic developers. Dr. Fleming has
authored the book, Optimizing Development of Therapies for Diabetes and a wide
variety of scientific and policy publications. He has served as an invited
editorialist to The New England Journal of Medicine and as a commentator on
National Public Radio.
Company CEO Jacob BenArie commented, As we continue to move
towards advanced stage trials of our technology, the need to ensure our research
is not only scientifically sound, but also compliant with senior medical
regulatory approval organizations is of paramount importance. With the advice
and guidance of Dr. Fleming we feel certain that we can focus our efforts
efficiently in order to maximize our ability to achieve our stated goals as
quickly as possible.
Dr. Fleming responded, I am honored to support a program that
not only has major potential for helping patients but is driven by fascinating,
elegant science. I am focusing my passion and energy around solutions to restore
normal insulin secretion in people with diabetes, which is the fundamental unmet
clinical need stretching across the entire spectrum of diabetes. I believe
Orgenesis can advance Sarah Ferber s technology into a breakthrough treatment if
not cure of T1 diabetes..
Orgenesis invites interested readers to visit our website at
www.orgenesis.com to find out more about the
Company and its goal to bring about the end of diabetes as we now know it.
Further details of the Company s business, finances,
appointments and agreements can be found as part of the Company s continuous
public disclosure as a reporting issuer under the Securities Exchange Act of
1934 filed with the Securities and Exchange Commission s ( SEC ) EDGAR database.
For more information visit: www.orgenesis.com.
About Orgenesis Inc. (OTCBB: ORGS)
development stage company with a novel therapeutic technology that employs a
molecular and cellular approach directed at converting a patient s own liver
cells into functional insulin producing cells, as a treatment for diabetes. The
Company believes that converting the diabetic patient s own tissue into
insulin-producing cells overcomes the problem of donor shortage and removes the
risk of transplant rejection. If successful, this could mean the end of diabetes
as we now know it. For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements which
are not purely historical. Such forward-looking statements include, among other
things, the expectations of management that our regeneration technology can be
developed as therapeutic treatment for diabetes. No assurance can be given that
any of the events anticipated by the forward-looking statements will occur or,
if they do occur, what benefits the Company will obtain from them. Actual
results could differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the inherent
uncertainties associated with new projects and development stage companies
.which include, without limitation, the potential failure of development
candidates to advance through preclinical studies or demonstrate safety and
efficacy in clinical testing and the ability to pass clinical trials so as to
move on to the next phase, our ability to retain key employees and our ability
to finance development or satisfy the rigorous regulatory requirements for new
medical procedures. Competitors may develop better or cheaper alternatives to
our products. These forward-looking statements are made as of the date of this
news release, and we assume no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ from those
projected in the forward-looking statements. Investors should refer to the risk
factors disclosure outlined in our periodic reports filed from time-to-time with
the Securities and Exchange Commission.
On Behalf of the Board
Vered Caplan, Chairperson
Email: orgs@crescendo-ir.com
Tel: +1-877-560-9060
Web: www.orgenesis.com